Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 183

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 183
---
,212,609 |   |

See accompanying notes to the consolidated financial statements.

F-3

REVELATION BIOSCIENCES, INC.
Consolidated Statements of Operations

|                                                                               |     | Year Ended   
 December 31, |        2024 |   |     |   |       2023 |   |
|:------------------------------------------------------------------------------|:----|:-------------|------------:|:--|:----|:--|-----------:|:--|
| Operating expenses:                                                           |     |              |             |   |     |   |            |   |
| Research and development                                                      |     | $            |   3,548,996 |   |     | $ |  4,145,902 |   |
| General and administrative                                                    |     |              |   4,426,113 |   |     |   |  4,510,762 |   |
| Total operating expenses                                                      |     |              |   7,975,109 |   |     |   |  8,656,664 |   |
| Loss from operations                                                          |     |              |  (7,975,109 | ) |     |   | (8,656,664 | ) |
| Other (expense) income:                                                       |     |              |             |   |     |   |            |   |
| Change in fair value of warrant liability                                     |     |              |      81,441 |   |     |   |  8,328,937 |   |
| Other (expense) income, net                                                   |     |              |  (7,144,868 | ) |     |   |    207,473 |   |
| Total other (expense) income, net                                             |     |              |  (7,063,427 | ) |     |   |  8,536,410 |   |
| Net loss                                                                      |     | $            | (15,038,536 | ) |     | $ |   (120,254 | ) |
| Net loss per share, basic and diluted                                         |     | $            |      (87.68 | ) |     | $ |      (8.44 | ) |
| Weighted-average shares used to compute net loss per share, basic and diluted |     |              |     171,510 |   |     |   |     14,246 |   |

See accompanying notes to the consolidated financial statements.

F-4

RE